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Abstract
Background: Tobacco smoking is the main risk factor of chronic obstructive pulmonary disease (COPD) but not all smokers
develop the disease. An abnormal pulmonary and systemic inflammatory response to smoking is thought to play a major
pathogenic role in COPD, but this has never been tested directly.
Methods: We studied the systemic biomarker and leukocyte transcriptomic response (Affymetrix microarrays) to smoking
exposure in 10 smokers with COPD and 10 smokers with normal spirometry. We also studied 10 healthy never smokers (not
exposed to smoking) as controls. Because some aspects of COPD may differ in males and females, and the inflammatory
response to other stressors (infection) might be different in man and women, we stratified participant recruitment by sex.
Differentially expressed genes were validated by q-PCR. Ontology enrichment was evaluated and interaction networks
inferred.
Results: Principal component analysis identified sex differences in the leukocyte transcriptomic response to acute smoking.
In both genders, we identified genes that were differentially expressed in response to smoking exclusively in COPD patients
(COPD related signature) or smokers with normal spirometry (Smoking related signature), their ontologies and interaction
networks.
Conclusions: The use of an experimental intervention (smoking exposure) to investigate the transcriptomic response of
peripheral leukocytes in COPD is a step beyond the standard case-control transcriptomic profiling carried out so far, and has
facilitated the identification of novel COPD and Smoking expression related signatures which differ in males and females.
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Introduction
Tobacco smoking is the major risk factor for Chronic
Obstructive Pulmonary Disease (COPD) [1]. Yet, only a
proportion of smokers, so called ‘‘susceptible smokers’’, develop
the disease [2]. The genetic and epigenetic background of each
smoker is likely to regulate the type and intensity of his/her
inflammatory response to smoking [1,3–5]. In ‘‘susceptible
smokers’’, this response is thought to be ‘‘enhanced’’, both in the
lungs [6] and in the systemic circulation [7], and is believed to
drive disease progression [1,6]. However, despite the wide
acceptance of this notion [1], no previous study has actually
studied the ‘‘response’’ to smoking (i.e., the specific inflammatory
changes that occur before and after smoking) in susceptible
smokers (i.e., patients with COPD) and resistant smokers (i.e.,
smokers with normal spirometry). Rather, available evidence
compares a number of inflammatory markers in these two groups
of smokers ‘‘after’’ many years of smoking exposure [6].
To address this gap in knowledge, we compared a number of
systemic inflammatory biomarkers and the transcriptome of
circulating leukocytes, before and after smoking in susceptible
(COPD patients) and resistant smokers. We hypothesized that
smoking exposure will induce a different inflammatory signature,
at the cellular, protein and/or transcriptome levels, in these two
groups of smokers. Importantly, because several previous reports
suggest that there may be significant gender differences in the
natural history of COPD [8–10] and some experimental
observations show that the leukocyte transcriptional response to
other acute stressors (infection) is different in males and females
[11], we recruited participants stratified by sex.
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Methods
Data S1 presents an extended explanation of the Methods used.
Design, Participants and Ethics
In this prospective and controlled study, we included 30
volunteers stratified by smoking history, presence of COPD [12]
and sex. All COPD patients were clinically stable. The Ethics
Committee the Hospital Clinic de Barcelona approved the study
protocol and all participants signed their informed consent.
Acute Smoking Exposure Test (ASET)
Current smokers were asked to refrain from smoking for, at
least, 8 hours before the ASET. Exhaled carbon monoxide
concentration was measured (SC01-STK, CO SmokeCheck
Monitor, Care Fusion, San Diego, US) to confirm smoking
abstinence. All participants fasted overnight. A catheter was
inserted in a peripheral vein and, based on previous studies in
healthy subjects [13,14], smokers were asked to smoke 2 cigarettes
(Nobel tar content 9 mg, nicotine 0.7 mg and carbon monoxide
9 mg, Altadis S.A. Spain) in 30 minutes under the direct
supervision of an investigator. Venous blood samples were
obtained before (T0), 30 (T30) and 180 minutes (T180) after
smoking. Plasma and buffy coat were separated immediately by
centrifugation at 400 g66 minutes. Plasma was stored at 270uC
until analysis. Erythrocytes were lysed, leukocytes washed, lysed in
RLT buffer and stored at 270uC for later RNA extraction.
Participants remained at rest for the duration of the test.
Measurements
Forced spirometry. Forced spirometry was measured ac-
cording to international recommendations [15]. Reference values
correspond to a Mediterranean population [16].
Circulating inflammatory markers. Total white blood
cells counts were quantified with an ADVIA-2120 system
(Siemens, Germany). The plasma concentration of C-Reactive
Protein (CRP) was determined by ultra-sensitive quantitative
turbidimetric test (Bayer Diagnostics, Germany), and those of
interleukin (IL)-6 (IL-6) and IL-8 by high sensitivity ELISA
(Invitrogen, USA). Blood carboxyhemoglobin levels were deter-
mined with a Rapid Point 500 Blood-Gas-System (Siemens,
Germany).
Leukocyte mRNA profile. RNA was extracted using
RNeasy Mini Kit (Qiagen, Valencia, US) following manufacturer
instructions. RNA integrity was assessed with an Agilent 2100
Bionalyzer (Agilent Technologies). All samples had a RIN above 8.
The 60 RNA samples were hybridized to Affymetrix HG-U219
array plate, which enables the performance of up to 96 arrays at
one time, following Affymetrix’s protocols. Microarray data has
been deposited in the GEO NCBI database (accession code
GSE55962).
Array validation by real time PCR. Selected genes were
subjected to real-time quantitative PCR (q-PCR) for independent
confirmation of relative expression levels in each group using
Taqman assays on demand, actin as a housekeeping gene, and
relative quantification was performed with the 2(DCP) method [17].
Data analysis
qPCR and systemic biomarker results are summarized as mean
6 standard deviation, proportions or range, as appropriate.
Clinical variables were compared across groups using unpaired
tests (Mann-Whitney, Kruskal-Wallis). Paired tests (Wilcoxon)
were used to compare T0 and T180 results within each group.
Differential gene expression was investigated using Rank Prod
[18]; probe-sets with FDR (False Discovery Rate) values,0.05
were considered significant. Principal components analysis (Par-
tekH Pro) was used to explore visually global effects on
transcription. DAVID (www.david.abcc.ncifcrf.gov) [19,20] was
used to estimate the functional over-representation of the
significant genes in the Gene Ontology Biological Process database
(www.geneontology.org). Interaction networks were constructed
using Ingenuity Pathways Analysis (IPA, www.ingenuity.com)
based on the Ingenuity Pathways Knowledge Base (IPKB) [21].
Cytoscape (www.cytoscape.org) was used to analyze and display
correlations results graphically [22,23].
Results
Participant Characteristics
Participants showed the differences in sex, smoking history and
lung function expected from the stratified recruitment strategy of
the study (Table 1). Of note: (1) age was similar in COPD patients
and smokers with normal spirometry; (2) airflow limitation in
COPD patients ranged from moderate to severe. Despite that it
was similar in males and females with COPD, the latter were older
(p = 0.02) and tended to have smoked less (p = 0.07); and (3)
cumulative smoking exposure was higher in males with COPD
than in male controls (p = 0.01), although this was not observed in
females.
Biomarker Response to Smoking
At baseline, carboxyhemoglobin levels were lower (p,0.001) in
non-smokers (NS) than in smokers with normal spirometry (S) or
with COPD, and they increased further thirty minutes after
smoking (Figure 1, panel A). Circulating leukocyte counts at T0
were higher (p = 0.02) in COPD than in controls, and they did not
change at T180 in any group (Figure 1, panel B); likewise, we did
not observed any significant change after smoking in circulating
neutrophils, lymphocytes (CD3+), CD4+ T cells, CD8+ T, CD19+
B cells or NK populations (data not shown). Mean CRP (Figure 2,
panel C) and IL-6 levels (Figure 1, panel D) were within the
normal range [7] in all groups and time points. IL-8 values were
below the lower detection limit in all participants, both before and
after smoking (data not shown). Finally, we did not observe
significant sex differences in any of these biomarkers, either before
or after smoking.
Leukocyte Transcriptomic Response to Smoking
Principal component analysis (PCA) allows the visualization of
differences within a multidimensional data set. Here, a PCA of the
expression values of those genes that show the largest variability
across all experimental groups (COPD, S and NS) at baseline
demonstrated a clear segregation of the leukocyte transcriptome
profile by sex (Figure 2, Panel A). Hence, further statistical
differential analyses were performed separately by gender, as
previously described [24]. Figure 2 (Panels B1 and B2) presents the
number of differentially expressed (DE) genes between T0 and
T180 (red and green figures indicate up or down DE, respectively)
in NS, S and COPD stratified by sex (Table S1 presents the
complete list of DE genes). Overall, transcriptomic changes were
of moderate intensity (log ratio ranged between 0.95 and 0.4).
Unsupervised clustering of DE genes in COPD segregated T0 and
T180 samples adequately, both in females (n = 57) and males
(n = 110) (Figure S1, panels A and B, respectively) indicating that
the Rank Prod statistical analysis used here identified clear gene
signatures associated with acute smoking exposure.
Systemic Inflammatory Response to Smoking in COPD
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Identification of COPD and Smoking related
genes. BioVenn diagrams in Figure 2 present the number of
DE genes from T0 to T180 that were shared (or not) between
groups (NS, S and COPD), both in females (Panel C1) and males
(Panel C2). Given that NS did not smoke, genes that were DE
from T0 to T180 in this group (36 in females and 63 in males)
were consider to represent time-dependent changes, and were
therefore excluded from any further analysis investigating the
Table 1. Characterization of participants by sex (mean6SD).
COPD Smokers Non Smokers
N (male/female) 9 (5/4) 11 (6/5) 10 (5/5)
Age , years
Male 5565 5162 5566
Female 6863* 5868 5865
BMI, Kg/m2
Male 26.463.4 25.061.7 26.461.1
Female 29.261.6 24.364.2 27.566.2
Pack/year
Male 706211 24614 0
Female 40611 3468 0
FEV1/FVC, %
Male 6164.91 7764 8162.2
Female 5364.91 7462.7 7863.9
FEV1, % reference
Male 646121 93612 96612
Female 63614 84611 88612
Asterisk indicate p,0.05 between COPD males and females, 1 indicates p,0.05 between COPD patients and smoker controls.
doi:10.1371/journal.pone.0097491.t001
Figure 1. Median (and IQR) values of blood carboxy-hemoglobin (panel A), circulating leukocytes (panel B), C-reactive protein serum
levels (panel C) and IL-6 (panel D) in COPD patients, smoker (S) and non-smoker (NS) controls, before (T0) and 30 min. (T30) or
180 min. (T180) later. For further explanations, see text.
doi:10.1371/journal.pone.0097491.g001
Systemic Inflammatory Response to Smoking in COPD
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response to smoking in S or COPD. Likewise, we operationally
considered that those genes that were DE in response to smoking
only in COPD patients represent COPD related genes, whereas
those genes DE in response to smoking only in smokers with
normal spirometry represent Smoking related genes. Accordingly, we
identified 29 COPD related genes in females (78 in males), and 61
Smoking genes in females (16 in males) (Figure 2, Panels C1 and
C2, respectively). Table 2 lists the top 10 susceptibility and
resistance genes ordered by log ratio after smoking, direction of
change and sex.
Additionally, we investigated if baseline differences in gene
expression between groups (S vs. COPD) and/or sex (male vs.
female) influence the transcriptional response to smoking. Results
are explained in detail in the data S1 (and Tables S2 and S3) but,
by and large, DE at baseline was only marginally related to the
transcriptomic response to smoking.
COPD and Smoking related genes shared by males and
females. We identified five COPD related genes shared by
males and females: (1) WIPF1 (mean log ratio =20.479), an
important regulator of the immunological synapsis formation and
T cell activation[25]; (2) BCL2A1 (mean log ratio =20.538), that
regulates p53tumor suppression induced apoptosis [26]; (3) SGK1
(mean log ratio =20.512), whose up regulation is involved in
hypertension, obesity, diabetes, thrombosis, stroke, fibrosing
disease, infertility and tumor growth, and its inhibition mediates
skeletal muscle homeostasis and function [27]; (4) ZNF397 (mean
log ratio = 0.551), thought to have a role in centromere formation
and gene transcription [28]; and, finally, (5) CLK1 (mean log
ratio = 0.589), an alternative splicing factor induced by hypoxia
[29].
Similarly, we identified two Smoking related genes shared by
males and females: POU2AF1 (log ratio =20.40), a nuclear factor
responsible of immunoglobulin transcription regulation [30], and
XYLT1 (log ratio = 0.45), the initial enzyme responsible of GAG
biosynthesis that has been associated with tissue remodeling [31].
Gene Ontologies Associated with COPD and Smoking
related genes. We used DAVID [19,20] to identify enriched
gene ontologies (% FDR,25) associated with the COPD
susceptibility and resistance genes identified above. In females,
ontologies enriched in COPD related genes (n = 29) included genes
Figure 2. Panel A: Principal component analysis (PCA) of those genes with the largest variability of expression values across the experimental groups
(COPD patients, smokers (S) and non-smokers (NS)) at baseline (T0). Because the sex effect observed, further analysis was stratified by sex (right and
left columns.) Panels B1 (females) and B2 (males) present the number of differentially expressed (DE) genes from T0 to T180 in the three groups of
participants studied. Red and green figures indicate up and down-regulation, respectively. Panels C1 (females) and C2 (males) show a BioVenn
diagram (www.cmbi.ru.nl/cdd/biovenn) with the number of DE genes shared between COPD, S and NS controls. For further explanations, see text.
doi:10.1371/journal.pone.0097491.g002
Systemic Inflammatory Response to Smoking in COPD
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Table 4. Gene ontology enrichment analysis, by sex. Females ontologies/genes associated with Smoking.
Term Genes % FDR p value
GO:0006955 immune response CYBB, POU2AF1, IL18RAP, CST7, ETS1, BCL2, LILRB4, TGFBR3, TNFSF14, CLEC4D 0.7 4.50E-04
GO:0043065 positive regulation of apoptosis ADRB2, ETS1, MMP9, KLF10, BCL2, TNFSF14, FADD, RRM2B 0.9 5.70E-04
GO:0043068 positive regulation of programed cell death ADRB2, ETS1, MMP9, KLF10, BCL2, TNFSF14, FADD, RRM2B 0.9 6.00E-04
GO:0010942 positive regulation of cell death ADRB2, ETS1, MMP9, KLF10, BCL2, TNFSF14, FADD, RRM2B 0.9 6.10E-04
GO:0051270 regulation of cell motion ETS1, IL6ST, MMP9, BCL2, TGFBR3 6 4.00E-03
GO:0051272 positive regulation of cell motion ETS1, IL6ST, MMP9, BCL2 7 4.00E-03
GO:0042127 regulation of cell proliferation ADRB2, FOSL2, ETS1, IL-6ST, KLF10, BCL2, CHST11, TGFBR3, ING1 7 5.00E-03
GO:0042981 regulation of apoptosis ADRB2, ETS1, MMP9, KLF10, BCL2, CHST11, TNFSF14, FADD, RRM2B 8 5.00E-03
GO:0043067 regulation of programmed cell death ADRB2, ETS1, MMP9, KLF10, BCL2, CHST11, TNFSF14, FADD, RRM2B 8 6.00E-03
GO:0010941 regulation of cell death ADRB2, ETS1, MMP9, KLF10, BCL2, CHST11, TNFSF14, FADD, RRM2B 9 6.00E-03
GO:0045926 negative regulation of growth ADRB2, BCL2, CDA, ING1 9 6.00E-03
GO:0005976 polysaccharide metabolic process XYLT1, IL6ST, CHST11, MGAM 10 6.00E-03
GO:0048643 positive regulation of skeletal muscle tissue
development
ADRB2, BCL2 15 0.01
GO:0045844 positive regulation of striated muscle
development
ADRB2, BCL2 19 0.01
GO:0048636 positive regulation of muscle development ADRB2, BCL2 19 0.01
GO:0051094 positive regulation of developmental process ADRB2, ETS1, IL-6ST, KLF10, BCL2 21 0.01
Bold italic text indicates up regulated genes and normal text indicates down regulated genes in response to smoking.
doi:10.1371/journal.pone.0097491.t004
Table 5. Gene ontology enrichment analysis, by sex. Males ontologies/genes associated with COPD.
Term Genes % FDR p value
GO:0006955 immune response GPR183, IL1R2, SH2D1A, KYNU, CLEC4E, THEMIS, SNCA, EOMES, TGFBR3, CLEC4D, CD24 1 9.00E-04
GO:0040012 regulation of locomotion SPAG9, S1PR1, SNCA, TGFBR3, CBLL1, TRIB1 3 1.71E-03
GO:0030334 regulation of cell migration SPAG9, S1PR1, TGTBR3, CBLL1, TRIB1 10 7.06E-03
GO:0051270 regulation of cell motion SPAG9, S1PR1, TGTBR3, CBLL1, TRIB1 16 1.00E-02
GO:0030098 lymphocyte differentiation GRP183, THEMIS, EOMES, CD24 16 1.00E-02
GO:0001824 blastocyst development HOPX, EOMES, TGFBR3 23 2.00E-02
Bold italic text indicates up regulated genes and normal text indicates down regulated genes in response to smoking. Analysis could not be done for ontologies/genes
associated with COPD resistance in males due to the small number of DE genes (n = 16) identified in smokers with normal spirometry.
doi:10.1371/journal.pone.0097491.t005
Table 3. Gene ontology enrichment analysis, by sex. Females ontologies/genes associated with COPD.
Term Genes % FDR p value
GO:0009991 response to extracellular stimulus FOS, MLL5, JUN, KLF4 7 5.20E-03
GO:0045893 positive regulation of transcription, DNA-dependent FOS, MLL5, JUN, RBM4, KLF4 9 6.74E-03
GO:0051254 positive regulation of RNA metabolic process FOS, MLL5, JUN, RBM4, KLF4 9 6.94E-03
GO:0060395 SMAD protein signal transduction FOS, JUN 12 0.01
GO:0045941 positive regulation of transcription FOS, MLL5, JUN, RBM4, KLF4 15 0.01
GO:0010628 positive regulation of gene expression FOS, MLL5, JUN, RBM4, KLF4 17 0.01
GO:0007611 learning or memory FOS, JUN, PAFAH1B1 18 0.01
GO:0045935 positive regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process FOS, MLL5, JUN, RBM4, KLF4 21 0.02
GO:0051173 positive regulation of nitrogen compound metabolic process FOS, MLL5, JUN, RBM4, KLF4 23 0.02
GO:0010557 positive regulation of macromolecule biosynthetic process FOS, MLL5, JUN, RBM4, KLF4 24 0.02
Bold italic text indicates up regulated genes and normal text indicates down regulated genes in response to smoking.
doi:10.1371/journal.pone.0097491.t003
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that were mostly down regulated (Table 3). Of note, MLL5, JUN
and FOS, were involved in most of the ontologies. It is known that
FOS and JUN dimerize to form the transcription factor complex
AP-1 a key player in the regulation of several biological processes
[32]. In keeping with this we observed that enriched ontologies
included regulation of transcription control, metabolism of nucleic
acids and biosynthetic processes (Table 3) as well as ontologies
related with the immune system, such as SMAD signaling and
response to extracellular stimulus. On the other hand, ontologies
enriched in Smoking related genes in females (n = 61) included both up
and down-regulated genes, and were related with the immune
system, cell cycle, cellular growth, apoptosis and cell locomotion
(Table 4). The former included genes involved in T cell activation
(ETS1 and TNFSF14) and antigen presentation control (CYBB
and CST7).
On the other hand, in males COPD related genes (n = 78) were
related to immune system, cellular locomotion and cellular
activation ontologies (Table 5). Interestingly, some of these
ontologies were similar to those identified in females as Smoking
related ontologies but with an opposite DE sign (up vs. down-
regulation). For instance, as shown in Table 5, genes involved in
cell migration were mainly activated in response to smoking in
males with COPD but mostly repressed in female S with normal
lung function. The ontology enrichment analysis of Smoking related
genes in males failed to obtain significant terms because of the small
number of genes identified (n = 16) (Figure 2, panel C2).
Expression Correlation Networks of COPD and Smoking
related Genes. We used Cytoscape (plug-ins Expression
Correlation and Bingo) [22] to explore if the expression of the
COPD and Smoking related genes identified above were correlated
(Pearson r$0.8) and form networks that have coordinated
functionality. We found that, in females, COPD related genes indeed
formed several correlation networks of different size (Figure 3,
panels A and B). Some of them included genes that form
functional cores (arrows) because they belong to the same
ontologies. For instance, MLL5, JUN and FOS define a functional
core of (repressed) genes (Panel A) that belong to three ontologies:
GO60395 (SMAD protein signal transduction, p value = 0.0001),
GO6306 (DNA methylation, p value = 0.0003) and GO6305
(DNA alkylation, p value = 0.0003). On the other hand,
PAFAH1B1, ELMOD2 and RABEP1 formed a functional core
of up-regulated susceptibility genes (panel B) participating in
GO16044 (cellular membrane organization, p = 0.001). Overall,
these results confirm, expand and support our previous analysis
Figure 3. Expression correlation networks (Pearson r$0.8) of COPD related genes in females (Panels A and B) and males (Panels C
and D). Red and green figures indicate up and down-regulation of expression, respectively. Arrows point genes forming functional clusters identified
in the network. For further explanations, see text.
doi:10.1371/journal.pone.0097491.g003
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using DAVID. Figure 4 depicts the correlation networks of Smoking
related genes in females. Two down-regulated networks were
identified containing ontologies related to GO44237 cellular
metabolic process (p = 0.015) and GO42221 response to chemical
stimulus (p = 0.0005) among others. A large positive correlation
network was identified, containing several ontologies as GO7275
multicellular organismal development (p = 0.0039) and GO50794
regulation of cellular process (p = 0.006).
In males, COPD related genes form (Figure 3): (1) a functional core
of repressed genes (arrows, Panel C) that belong to ‘‘Response to
chemical stimulus’’ (GO42221, p = 0.001); and, (2) a cluster
(arrows) of up-regulated genes (Panel D) involved in GO2376
(Immune system process, p = 0.007) and GO30097 (Hemopoiesis,
p = 0.0002). The network analysis of Smoking in males was not
possible because of the low number of genes identified (n = 16).
Interaction Network Analysis of COPD and Smoking
related genes. To infer interaction networks of COPD and
Smoking related genes we used Ingenuity Pathways Analysis (IPA), a
database of known molecule interactions [21]. In females, from the
61 Smoking genes (Figure 2, panel C1) IPA identified one significant
network (IPA p-score 55) (Figure 5, panel A) whose main
functional terms included organismal injury and abnormalities,
cell death and survival and cell morphology. We selected the ETS
gene, a central hub in this network, for independent validation by
real time PCR (qPCR); the later confirmed the observed
microarrays transcriptional change (Figure S2). Likewise, from
the 29 COPD related genes identified in females (Figure 2, panel
C1), IPA identified a network (p-score 43) enriched in cell death
and survival, lipid metabolism and small molecule biochemistry
functions (Figure 5, panel B). In this network, we selected FOS and
CXCL1 for independent qPCR validation; results (Figure S2)
confirmed changes in both CXCL1 (p = 0.01) and FOS (p = 0.07).
The low number of Smoking genes (n = 16) identified in males did
not allow obtaining significant networks in the IPA analysis. By
contrast, from the 78 COPD related genes identified in males
(Figure 2, panel C2), IPA identified two large networks. The first
one (IPA p-score 45) included infectious disease, cellular function
and maintenance, hematological system development and function
as main functional terms (Figure 5, panel C). The second one (p-
score 43) included DNA replication, recombination, cell cycle and
cell morphology terms (Figure 5, panel D). From these two
networks, we selected HLX, TRIB1 and BIRC3, known to be
involved in cell activation, cell migration and apoptosis respec-
tively, for qPCR validation (Figure S2).
Discussion
Despite that an abnormal inflammatory response to smoking is
believed to play a major pathogenic role in COPD [1], to our
knowledge this is the first study to directly compare the systemic
biomarker and transcriptomic leukocyte response to acute smoking
exposure in susceptible (i.e. COPD patients) and resistant smokers
(i.e., those with normal spirometry). By doing so, our results
provide several novel and potentially relevant observations. First,
we identified a differential transcriptomic pattern, both at baseline
and in response to smoking, in males and females, whose
implications go beyond COPD, as discussed below. Second, we
identified a number of COPD and Smoking related genes (signatures),
both in males and females, and we identified their enriched
ontologies and gene interaction networks. Yet, due to the relatively
small number of subjects studied, reproducibility in an indepen-
dent and larger set of COPD patients and smokers is needed.
Previous studies
Several previous studies have investigated the biological
response to acute smoking exposure in healthy subjects [13,14].
In fact, we designed the dose and timing of our ASET (see
Methods) mostly based on these previous experiences. Yet, to our
knowledge, no previous study has directly contrasted the
transcriptomic response of circulating leukocytes to ASET in
smokers with or without COPD. Bahr et al [33] compared the
basal leukocyte transcriptomic pattern in COPD patients and non-
Figure 4. Expression correlation networks (Pearson r$0.8) of Smoking genes in females. Arrows indicate genes identified by gene
ontology analysis in the network. Red and green indicate up and down-regulation, respectively. For further explanations, see text.
doi:10.1371/journal.pone.0097491.g004
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smoker controls, without exposing subjects to smoking or
considering potential sex differences. In our study, at baseline,
we identified 19 DE genes also identified by Bahr et al [33]
(C19orf59, ARHGAP18, C11orf75, CARD16, CLEC4D, FAIM3,
FCRL3, GYG1, GZMM, HOPX, MAL, MAPK14, MCTP1,
NELL2, RPS23, SAT1, SLC8A1, SNHG8, SPON2). Of note,
MLL5, JUN, RABEP1 and ZFAND6 were identified in our study
as COPD related genes in females and were also identified by
Bhattacharya et al [34] as COPD associated genes in peripheral
blood.
Interpretation of findings
Leukocyte transcriptomics changes after acute smoking expo-
sure were relatively low. This might not be surprising if this is
framed within the natural history of COPD, which takes decades
of smoking exposure to develop. In keeping with this, previous
peripheral blood transcriptomic studies in COPD also reported
small fold change differences [33,34].
The fact that our study involved an intervention (ASET) in
smokers with and without COPD, that it included never smokers
(who served as a control for time-related biological effects), and
that we stratified participants by sex prove to be key aspects of the
experimental design and of paramount importance to identify
different COPD and Smoking related signatures in males and female
smokers. In males, the COPD related signature included ontologies
related to the immune system (up-regulated) and cellular
locomotion (up-regulated), whereas only a few number of genes
(which limited ontology enrichment analysis) were associated with
Smoking. By contrast, in females the Smoking signature included
ontologies that were similar (but of opposite direction) to those
identified as COPD related in males, and that their COPD related
signature included down-regulation of the MLL5, FOS and JUN
genes, all of them involved in the inflammatory response.
Collectively, these observations suggest a tighter control of the
inflammatory response to smoking in females.
How these sex differences in leukocyte transcriptomics might
translate into the clinic is speculative but a number of clinically
relevant gender differences have been long recognized in COPD
[8–10]. For instance, previous studies of our group demonstrated
that lung function decline with age was significantly higher in
males than in females, both in healthy never smokers as well as in
smokers with COPD [35]. A different regulation of the inflam-
matory response in males and females as that proposed here may
well contribute to these observations. In fact, interestingly in the
Figure 5. Putative interaction networks identified by Ingenuity Pathway Analysis (IPA)[21], and their corresponding scores, in
female smoker controls COPD related in females (Panel A), Smoking in females (Panel B) and COPD related in males (Panels C and D).
For further explanations, see text.
doi:10.1371/journal.pone.0097491.g005
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context of this discussion, systemic levels of inflammatory
biomarkers appear reduced in females (vs. males) with COPD
[36].
The relevance of these observations for other common smoking
related diseases, such as cardiovascular disease [37–39] or lung
cancer [40–42], deserves further investigation. In fact, recent
publications support similar sex differences in other immune
related diseases, such as multiple sclerosis [43], and it is well
established that autoimmune diseases are particularly prevalent in
females [44]. All in all, therefore, these observations call for a
careful exploration and re-analysis of available COPD genetic
data by gender.
Finally, we used several network analysis techniques to infer
potential interactions among the identified COPD and Smoking
related genes and thus to get further insight into the pathobiology of
the disease. The expression correlation networks in conjunction
with gene ontology identified functional cores of differentially
expressed genes. The possible interaction networks between
differentially expressed genes identify by IPA (on the basis of
already know molecule interactions) showed good IPA p-scores
and their main gene hub changes were validated by qPCR. In
females, resistance genes networks included genes related to Gpcr
signaling (SIPR5, GPR56), inflammation and Th1 responses
(ETS-1, MMP9, TBX21), apoptosis (BCL2) and sensing of planar
aromatic hydrocarbons that are present in tobacco (AHR),
whereas the main hubs in their susceptibly gene networks include
the repression of JUN and FOS, both involved also in the
regulation of immune responses through the formation of the AP
transcription factor. Overall, therefore, these observations suggest
again a differential regulation of immune processes in females with
or without COPD. On the other hand, in males, we identified two
COPD related gene networks that involved, respectively, the
response to planar aromatic hydrocarbons (hub gene AHR) and
the immune response (hub gene RORA) on the one hand, and
Gpcr signaling, ubiquitinization (TRIB1, RAD23B, USP-15) and
apoptosis-autophagy (BIRC3, TRIM13, TRIM23) on the other,
which were validated by qPCR. Interestingly, other studies have
reported alterations in some of these processes in COPD [45–47].
Strengths and Limitations
Our study has strengths and limitations. The fact that, despite
the widespread assumption that COPD is characterized by an
abnormal response to smoking, this is the first study to investigate
this possibility specifically at the transcriptional level is a clear
strength. Likewise, the use of an active experimental intervention
(ASET) is a step beyond the standard transcriptomic case-control
studies [48] and has in fact facilitated the identification of novel
COPD and Smoking related genes in response to acute tobacco
exposure. Finally, the use of network analysis has allowed the
description of clear gender differences in the systemic inflamma-
tory response to smoking in COPD patients and Smokers, an
observation that may have implications beyond COPD in other
smoking-related diseases. Among its limitations, we acknowledge
that the transcriptomic changes after ASET were measured only in
circulating leukocytes, so it is possible that changes in the
pulmonary parenchyma may differ in type and/or intensity;
needless to say that ethical and logistic difficulties involved in
obtaining lung tissue samples before and after smoking are
notorious. Finally, we included in the study 30 volunteers but,
when stratified by presence of disease, smoking status and sex,
each subgroup includes 5 individuals only. Due to the relatively
small number of subjects studied, results need replication in an
independent and larger cohort of COPD patients.
Conclusions
This study shows that the transcriptomic response to smoke in
circulating leukocytes is different in smokers with and without
COPD, and also in males and females.
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